Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare

Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its haemophilia A gene therapy trial developed immune reactions, one of

Latest news

More from news
Approximately 9 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib. ... Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell Receptor (TCR) technologies; incl Juno's CD19 and CD22 directed CAR-T candidates. ... NewCo formation, collaboration. 760. Unum

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh. ... Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

  • Rubius Therapeutics adds to its board of directors Rubius Therapeutics adds to its board of directors

    Rubius Therapeutics adds to its board of directors. Francis Cuss and Catherine Sohn join the US biotech. ... Alongside Cuss, Catherine Sohn, currently non-executive chairman of BioEclipse Therapeutics, has also joined the biotech’s board.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    Rubius Therapeutics, a company focused on creating Red-Cell Therapeutics, has bolstered its senior team with the addition of four new hires. ... Chris and the rest of the team will play a pivotal role in bringing the promise of red cell therapeutics to

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Bone Therapeutics strengthens clinical development team. Dr Miguel Forte joins the firm as chief medical officer. ... Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell therapy will be a strong asset to our

  • David Epstein joins Flagship Pioneering as executive partner David Epstein joins Flagship Pioneering as executive partner

    In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... society. “ We look at the manufacturing challenges we are facing for emerging healthcare products, such as stratified protein therapeutics and

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics